motapizone has been researched along with cardiovascular agents in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (66.67) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fischer, W; Hanselle, U; Huhmann, W; Schulz, V; Zietsch, V | 2 |
| Schade, FU; Schudt, C | 1 |
1 trial(s) available for motapizone and cardiovascular agents
| Article | Year |
|---|---|
Inhibition of thrombocyte aggregation by oral motapizone and other drugs.
Topics: Adult; Antihypertensive Agents; Aspirin; Cardiovascular Agents; Female; Fibrinolytic Agents; Humans; Male; Platelet Aggregation; Pyridazines | 1986 |
2 other study(ies) available for motapizone and cardiovascular agents
| Article | Year |
|---|---|
Hypotensive and antiplatelet actions of motapizone depend on dose and time after ingestion.
Topics: Adult; Blood Pressure; Cardiovascular Agents; Dose-Response Relationship, Drug; Female; Fibrinolytic Agents; Heart Rate; Humans; Male; Platelet Aggregation; Pyridazines | 1986 |
The specific type III and IV phosphodiesterase inhibitor zardaverine suppresses formation of tumor necrosis factor by macrophages.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Cardiovascular Agents; Cells, Cultured; Cyclic Nucleotide Phosphodiesterases, Type 4; Epoprostenol; Isoenzymes; Lipopolysaccharides; Macrophages; Male; Mice; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Platelet Aggregation Inhibitors; Pyridazines; Pyrrolidinones; Rolipram; SRS-A; Tumor Necrosis Factor-alpha | 1993 |